The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
More top news
Nicky Morgan is expected to defend the proposal when she faces questions at the National Association of Head Teachers' annual conference.
Phone charges in the European Union will drop by about 75 per cent from today as part of an interim cap ahead of a full ban next year.
Councils in England and Wales wants compulsory flood-proofing measures put in place for new homes and businesses in at risk areas.